CBSC activates China manufacturing pipeline and advances MyCardia AT into final NMPA submission phase with Ebulent Medical.

Jan 15

Cardiac Biotech

Cardiac Biotech

Cardiac Biotech Solutions Activates China Production Pipeline for MyCardia AT and Moves into Final NMPA Submission Phase

CBSC activates China manufacturing pipeline and enters final NMPA submission phase for MyCardia AT cardiac monitoring device.
CBSC secures Health Canada license for CardioHolter AT with $375K order from Your Heart Protector Corp, expanding cardiac monitoring in Canada.

Sep 25

Cardiac Biotech

Cardiac Biotech

Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter AT

CBSC secures Health Canada license for CardioHolter AT, lands $375K order with Your Heart Protector Corp, expanding into Canadian market.

How can we help you?

Contact Us

© 2020-2026. Cardiac Biotech Solutions, Inc. - All rights reserved. | Designer

Get our news in your inbox!

Join our newsletter and we will send our news directly to you.